3D Bioprinting

rhCollagen enables an unlimited supply of tissues and organs

Regenerative medicine and tissue engineering have seen unprecedented growth in the past decade, driving the field of artificial tissue models towards a revolution in future medicine. 3D bioprinting is gaining momentum in many medicinal applications to address the need for complex scaffolds required for generation of tissues and organs suitable for transplantation.

CollPlant’s rhCollagen-based BioInks offer ideal characteristics for 3D bioprinting, including optimal rheology, increased safety profile, biocompatibility and tuneable physical properties.

CollPlant is advancing the development of 3D bioprinted tissues and organs, in-house and in collaboration with partners.

Bioprinting of soft tissue implant

 

In October 2018, we entered into a licensing agreement with United Therapeutics, a leader in the field, for use of CollPlant’s BioInks for the manufacture of 3D bioprinted lungs for transplant in humans. In September 2020, the collaboration was expanded to include 3D bioprinting of human kidneys for transplant.

3D bioprinting of trachea using CollPlant’s BioInk. Courtesy of United Therapeutics

 

30,000 organ transplants are done each year in the US, while 900,000 people die every year due to organ impairment. 3D bioprinting is expected to bridge this gap by allowing an unlimited supply of life-saving organs.

 

® 2020 CollPlant Biotechnologies Ltd. All rights reserved. Version: CPW 04-20